<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01292993</url>
  </required_header>
  <id_info>
    <org_study_id>LX4211.1-103-DDI</org_study_id>
    <secondary_id>LX4211.103</secondary_id>
    <nct_id>NCT01292993</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, 3-Period, 3-Treatment, Single-dose Crossover Study to Evaluate the Pharmacokinetic Interaction of LX4211 and Metformin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of LX4211 and metformin on each other
      when given at the same time as single doses to healthy human subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of LX4211 and metformin after concurrent single-dose administration</measure>
    <time_frame>Up to 43 days, including screening</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary glucose excretion</measure>
    <time_frame>Up to 43 days, including screening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>Up to 43 days, including screening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial glucose</measure>
    <time_frame>Up to 43 days, including screening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>Up to 43 days, including screening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peptide YY</measure>
    <time_frame>Up to 43 days, including screening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon-like peptide (GLP-1)</measure>
    <time_frame>Up to 43 days, including screening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose-dependent insulinotropic peptide</measure>
    <time_frame>Up to 43 days, including screening</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg LX4211</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000 mg metformin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg LX4211 + 1000 mg metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400 mg LX4211</intervention_name>
    <description>400 mg of LX4211 given as a solid oral dose form</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1000 mg metformin</intervention_name>
    <description>1000 mg metformin given as a solid oral dose form</description>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥18 to ≤55 years of age. Females must be of non-childbearing potential.

          -  Body mass index (BMI)≥18 to ≤35 kg/sq m

          -  Able to provide written consent

          -  Vital signs within sponsor-defined ranges

        Exclusion Criteria:

          -  Use of any medication, including any prescription, over-the-counter, herbal tea, or
             other supplements within 5 days of dosing

          -  No investigational agent or study treatment within 30 days prior to Day 1.

          -  No protein or antibody-based therapeutic agents within 3 months prior to screening

          -  Use of any tobacco product

          -  History of bariatric surgery or any gastrointestinal surgery that may induce
             malabsorption

          -  History of any major surgery within 6 months prior to screening

          -  History of any serious adverse reaction or hypersensitivity to metformin or LX4211.

          -  History of renal disease or significantly abnormal kidney function test

          -  History of hepatic disease or significantly abnormal liver function test

          -  History of any active infection within 30 days prior to Day 1

          -  History of any surgical or medical condition or clinically significant laboratory or
             physical finding

          -  Positive urine glucose at Screening

          -  Use of drugs or alcohol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ikenna Ogbaa, MD</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2011</study_first_submitted>
  <study_first_submitted_qc>February 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2011</study_first_posted>
  <last_update_submitted>March 29, 2011</last_update_submitted>
  <last_update_submitted_qc>March 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ikenna Ogbaa, MD</name_title>
    <organization>Lexicon Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

